Short answer
Vertex Pharmaceuticals (VRTX) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Suketu Upadhyay will leave Vertex’s board after the 2026 annual meeting for scheduling conflicts tied to his forthcoming Incyte CFO role.
Vertex Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Suketu Upadhyay will leave Vertex’s board after the 2026 annual meeting for scheduling conflicts tied to his forthcoming Incyte CFO role
- Departure explicitly unrelated to disagreements over Vertex operations, policies or practices
- Board plans to reduce membership to ten directors following his departure
- Proxy materials amended to remove Upadhyay; remaining nominees and shareholder voting items unchanged
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vertex Pharmaceuticals 8-K filings
Get the next VRTX 8-K as it lands
Follow VRTX for push alerts, or ask the research agent what this filing means.